The Company’s notes receivable, net consists of investments in loans to buyers of charged-off and nonperforming receivable portfolios through HGC and financing of laboratory equipment sales through ALT.

As of June 30, 2026 and December 31, 2025, the Company’s outstanding notes receivable balance related to loans to buyers of charged-off and nonperforming receivable portfolios, net of unamortized deferred fees and costs on originated loans, and adjusted for the allowance for credit losses was $3.9 million and $8.8 million, respectively. The activity during the six months ended June 30, 2026 includes the additional investment in notes receivable of approximately $1.3 million, which was offset by principal payments made by borrowers of approximately $2.7 million and a $3.5 million increase to the allowance for credit losses, related to the Board's decision to wind down the Specialty Lending segment.

As of June 30, 2026 and December 31, 2025, the Company’s outstanding notes receivable balance related to financing of laboratory equipment sales, net of unamortized deferred fees and costs on originated loans and adjusted for the reserve for credit losses was $0.8 million and $0.6 million, respectively. The activity during the six months ended June 30, 2026 includes the investment in notes receivable of approximately $0.7 million, which was offset by principal payments made by purchasers of $0.5 million and an immaterial amount of deferred financing fees, and allowance for credit losses.

The table below shows the Company’s lending activity for the six months ended June 30, 2026 (in thousands):



Notes receivable as of December 31, 2025	$	9,804
Investment in notes receivable		1,972
Principal repayments		(3,145	)
Notes receivable, as of June 30, 2026		8,631
Deferred financing fees and costs, net		(15	)
Allowance for credit losses		(3,853	)
Notes receivable, net, as of June 30, 2026	$	4,763

In accordance with ASC 326, the Company performs a review of notes receivable on a quarterly basis. During the six months ended June 30, 2026 and in connection with the Board's decision to wind down the Specialty Lending segment, the Company recorded an increase of $3.5 million to the provision for credit losses in selling, general and administrative expense on the consolidated statement of income. As of June 30, 2026 and December 31, 2025, the amortized cost basis of notes receivable in nonaccrual status was $4.6 million and $4.8 million, respectively.